

Supplementary Table 1: Therapies targeting PI3K/AKT/mTOR pathway

| Treatment | Number of patients (%) | PR (%) | SD_{≥6} months/PR (%) |
|--|-------------------------------|---------------|--------------------------------------|
| All | 66 (100) | 11 (100) | 4 (100) |
| Single agent mTORC1 inhibitors (sirolimus, temsirolimus) | 17 (26) | 0 (0) | 0 (0) |
| mTORC1 inhibitors (sirolimus, everolimus, temsirolimus) combined with other targeted therapy | 8 (12) | 3 (27) | 0 (0) |
| mTORC1 inhibitors (sirolimus, temsirolimus) combined with chemotherapy +/- other targeted therapy | 27 (41) | 8 (73) | 2 (50) |
| Single agent PI3K inhibitors | 7 (10.5) | 0 (0) | 1 (25) |
| Single agent dual PI3K and mTOR kinase inhibitors | 2 (3) | 0 (0) | 0 (0) |
| Single agent AKT inhibitors | 2 (3) | 0 (0) | 0 (0) |
| PI3K inhibitors combined with MEK inhibitors | 2 (3) | 0 (0) | 1 (25) |
| PI3K inhibitors combined with chemotherapy | 1 (1.5) | 0 (0) | 0 (0) |